 The European Commission has approved Deciphera Pharmaceuticals Incs NASDAQ: DCPH Qinlock ripretinibfor adult patients with advanced gastrointestinal stromal tumor GIST who have received prior treatment with three or more kinase inhibitors, including imatinib. In September 2021, Qinlock was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib, to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST2. 